Pulmo, Harrison Flashcards

1
Q

Condition in which venous thrombi dislodge from their site of formation and emboli to pulmonary arterial circulation

A

PE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

PE in the setting of normal right heart function and normal systemic arterial pressure

A

Small to moderate PE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

PE in the setting of RV hypokinesis but normal systemic arterial pressure

A

Moderate to large PE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

PE in the setting of arterial hypotension and anatomically widespread TE

A

Massive PE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

PE: Gender predominance

A

F

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

PE: Acquired risk factor that has a greater risk of fatal PE

A

Cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

PE: Non-DVT specific risk factor that has a greater risk of fatal PE

A

Cerebrovascular disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

50% of DVT is due to (2)

A

1) Pelvic vein thrombosis

2) Proximal leg DVT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Vein thrombi that poses a lower risk of PE

A

Isolated calf vein thrombi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PE: First step in outpatient or ER setting with non-high clinical likelihood

A

D-dimer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

PE: Elevated D-dimer, next step is

A

Imaging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PE: First step for inpatients or with high likelihood

A

1) Chest CT with contrast

2) Lung scan if with renal insufficiency or renal contrast allergy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

COPD: Major risk factor

A

Cigarette smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

COPD, normal vs slightly reduced, vs markedly reduced levels of α1 antitrypsin: M allele

A

Normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

COPD, normal vs slightly reduced, vs markedly reduced levels of α1 antitrypsin: S allele

A

Slightly reduced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

COPD, normal vs slightly reduced, vs markedly reduced levels of α1 antitrypsin: Z allele

A

Markedly reduced

17
Q

COPD, normal vs slightly reduced, vs markedly reduced levels of α1 antitrypsin: Null allele

A

Absence

18
Q

COPD: Most common cause of exacerbation

A

Viral infections

19
Q

3 most common symptoms of COPD

A

1) Cough
2) Sputum production
3) Exertional dyspnea, frequently of long duration

20
Q

COPD: Pursed lip breathing

A

Emphysema

21
Q

Tripod position is in order to

A

Facilitate actions of SCM, scalene, and intercostal muscles

22
Q

Sign associated with paradoxical breathing

A

Hoover sign (inward movement of rib cage)

23
Q

Signs of cor pulmonale (6)

A

1) Peripheral edema
2) Ascites
3) Hepatic congestion
4) Elevated JVP
5) RV heave
6) 3rd heart sound

24
Q

T/F Chronic bronchitis without chronic airflow obstruction is not COPD

A

T

25
Q

T/F Asthma patients can also develop chronic (not fully reversible) airflow obstruction

A

T

26
Q

T/F Clubbing of fingers is not a sign of COPD

A

T

27
Q

In patients with COPD, newly developed clubbing is most likely explained by

A

Lung CA

28
Q

Hospitalization in COPD is recommended for (4)

A

1) Respiratory acidosis and hypercarbia
2) Significant hypoxemia
3) Severe underlying disease
4) Living situation not conducive to careful observation and delivery of prescribed treatment

29
Q

2 interventions demonstrated to influence the natural history of COPD

A

1) Smoking cessation

2) O2 therapy

30
Q

The only therapy demonstrated to decrease mortality in COPD

A

Supplemental O2

31
Q

COPD: Arterial pH allows classification of ventilatory failure, which is defined as

A

pCO2 >45mmHg

32
Q

Principal determinant of morbidity in COPD

A

Degree of airway obstruction

33
Q

COPD: Patients who continue to smoke cigarettes experience an annual decline in FEV1 of

A

80-100mL

34
Q

COPD: Patients who quit smoking experience an annual decrease inFEC1 of

A

30mL

35
Q

COPD: Median survival for severe disease

A

4 years

36
Q

COPD: Severe disease is defined as

A

FEV1 less than 1L